Uric acid: Role in cardiovascular disease and effects of losartan

Current Medical Research and Opinion

Volumn 20, Issue 3, 2004, Pages 369-379

  Alderman, Michael ^a   Aiyer, Kala J V ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE

Author keywords

Angiotensin II antagonists; Cardiovascular disease; Hypertension; LIFE; Losartan; Purine metabolism; Uric acid

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALLOPURINOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENZBROMARONE; BENZIODARONE; BIOLOGICAL MARKER; CHLORTALIDONE; CHOLESTEROL; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; LOSARTAN; NITRIC OXIDE SYNTHASE; OXIPURINOL; PROBENECID; PURINE; RESERPINE; SALICYLIC ACID DERIVATIVE; SEROTONIN; SULFINPYRAZONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; URATE OXIDASE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

AEROBIC METABOLISM; BLOOD RHEOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; FLANK PAIN; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMATURIA; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASE; MORTALITY; NEPHROLITHIASIS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PREDICTION; REVIEW; RISK FACTOR; STROKE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; VASCULAR ENDOTHELIUM;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERURICEMIA; KIDNEY DISEASES; LOSARTAN; PURINES; RECEPTORS, ANGIOTENSIN; TREATMENT OUTCOME; URIC ACID;

EID: 1542510891     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125002982     Document Type: Review

References (93)

1. Gertler MM, Gam SM, Levine SA. Serum uric acid in relation to age and physique in health and coronary heart disease. Ann Intern Med 1951;34:1421-31
2. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34:144-50
3. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002;2:126-30
4. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988;224:549-55
5. Breckenridge A. Hypertension and hyperuricaemia. Lancet 1966;1:15-8
6. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995;141:637-44
7. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999;33:225-34
8. Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA et al. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987;147:645-9
9. Persky VW, Dyer AR, Idris-Soven E, Stamler J, Shekelle RB, Schoenberger JA et al. Uric acid: a risk factor for coronary heart disease? Circulation 1979;59:969-77
10. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991;59:364-8
11. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES 1 epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-10
12. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000;36:1072-8
13. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457-64
14. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475-82
15. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 1999;48:501-9
16. Watanabe S, Kanellis J, Nakagawa T, Han L, Ohashi R, Lan H et al. Reducing uric acid as a means to prevent cardiovascular and renal disease. Expert Opin Ther Patents 2002;12:193-9
17. Hoieggen A, Alderman MH, Kjeldsen S, Julius S, Devereux RB, de Faire U et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2003; in press
18. Sica DA, Schoolwerth AC. Renal handling of organic anions and cations and renal excretion of uric acid. In: Brenner B, Rector F, eds. The Kidney 2000:680-700
19. Steele TH. Hyperuricemic nephropathies. Nephron 1999;81 Suppl 1:45-9
20. Maesaka JK, Fishbane S Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998;32(6):917-33
21. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008-11
22. Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 1997;30:928-31
23. Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. Can J Cardiol 2000;16:779-89
24. Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med 2002;69:594, 597, 600-594, 597, 602
25. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973;132:401-10
26. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000;10:136-43
27. Alderman M. Uric acid in hypertension and cardiovascular disease. Can J Cardiol 1999;15(Suppl F):20F-22F
28. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13
29. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998;352:670-1
30. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18:1149-54
31. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertens 1998;16:761-9
32. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-7
33. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003;107:1951-3
34. Bickel C, Rupprecht HJ, Blankenberg S, Rippin G, Hafner G, Daunhauer A et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:12-7
35. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998;29:635-9
36. Beck LH. Requiem for gouty nephropathy. Kidney Int 1986;30:280-7
37. Gonick HC, Rubini MD, Gleason IO, Sommers SC. The renal lesion in gout. Arch Intern Med 1965;62:667-74
38. Talbott JH, Terplan KL. The kidney in gout. Medicine 1960;39:405-67
39. Ginsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J Clin Invest 1977;60:999-1007
40. Newland H. Hyperuricemia in coronary, cerebral and peripheral arterial disease: an explanation. Med Hypotheses 1975;1:152-5
41. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6
42. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997
43. Waring WS, Webb DJ, Maxwell SR. Effect of local hyperuricemia on endothelial function in the forearm vascular bed (abstract). Br J Clin Pharmacol 2000;49:511
44. Bulpitt CJ. Serum uric acid in hypertensive patients. Br Heart J 1975;37:1210-5
45. Selby JV, Friedman GD, Quesenberry CP, Jr. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990;131:1017-27
46. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000;35:746-51
47. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619-24
48. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-65
49. Mustard JF, Murphy EA, Ogryzlo MA, Smythe HA. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J 1963;89:1207-11
50. Hoieggen A, Fossum E, Reims H, Kjeldsen SE. Serum uric acid and hemorheology in borderline hypertensives and in subjects with established hypertension and left ventricular hypertrophy. Blood Press 2003;12:104-10
51. Newland H. Hyperuricemia in coronary, cerebral and peripheral arterial disease: an explanation. Med Hypotheses 1975;1:152-5
52. Johnson RJ, Schreiner GF. Hypothesis: the role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension. Kidney Int 1997;52:1169-79
53. Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001;87:333-9
54. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000;15:34-42
55. Gordon TP, Terkeltaub R, Ginsberg MH. Gout: crystal-induced inflammation. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. New York: Raven, 1988:775-83
56. Insel PA. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996:617-57
57. Sorensen LB, Levinson DJ. Clinical evaluation of benzbromarone: a new uricosuric drug. Arthritis Rheum 1976;19:183-90
58. Masbernard A, Giudicelli CP. Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J 1981;59:701-6
59. Pfister B, Imhof P, Wirz H. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers. Eur J Clin Pharmacol 1978;519:263-5
60. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98
61. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25
62. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000;160:2185-91
63. Tsunoda S, Kamide K, Minami J, Kawano Y. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens 2002;15:697-701
64. Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E et al. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 1997;62:194-202
65. Iwatani M, Wasada T, Katsumori K, Watanabe-Takahashi C, Kamatani N, Iwamoto Y. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics. Diabetologia 2000;43:814-5
66. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787-90
67. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47
68. Burnier M, Pechere-Bertschi A, Nussberger J, Waeber B, Brunner HR. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995;26:108-15
69. Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, Tanaka H et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002;41:793-7
70. Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268-71
71. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60
72. Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002;20:347
73. Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000;22:1186-203
74. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033-9
75. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6
76. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
77. Nikas S, Rizos E, Milionis H, Bairaktari E, Kalaitzidis R, Siamopoulos K et al. The effects of the addition of losartan on uric acid metabolism in patients receiving indapamide. J Renin Angiotensin Aldosterone Syst 2000;1:289-91
78. Soffer BA, Wright JT, Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-7
79. Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995;155:405-11
80. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 1997;280:839-45
81. Roch-Ramel F, Werner D, Guisan B. Urate transport in brush-border membrane of human kidney. Am J Physiol 1994;266:F797-F805
82. Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999;56:1879-85
83. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo -controlled studies. Circulation 2002;105:2619-24
84. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229-34
85. Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 1991;121:20-4
86. Rashid MA, William-Olsson G. Influence of allopurinol on cardiac complications in open heart operations. Ann Thorac Surg 1991;52:127-30
87. Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino Y, Mohri H. A clinical trial of allopurinol (Zyloric) for myocardial protection. J Thorac Cardiovasc Surg 1991;101:713-8
88. Day RO, Birkett DJ, Hicks M, Miners JO, Graham GG, Brooks PM. New uses for allopurinol. Drugs 1994;48:339-44
89. Ricardo SD, Bertram JF, Ryan GB. Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol. Exp Nephrol 1995;3:270-9
90. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6
91. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
92. Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Hieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf B, for the LIFE study group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kid Intl 2003. In press
93. Owens P, Kelly L, Nallen R, Ryan D, Fitzgerald D, O'Brien E. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide - a randomized controlled trial. J Hypertens 2000;18:339-45